Janney Montgomery Scott Defends DepoMed (DEPO) Amid Downgrade-Related Weakness
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
UBS Downgrades DepoMed Inc (DEPO) to Neutral
July 7, 2016 7:23 AM EDTUBS downgraded DepoMed Inc (NASDAQ: DEPO) from Buy to Neutral with a price target of $20.00.
Analyst Ami Fadia cited:
(1) We see risk to mgt's 2016 sales guidance of $490-520M and consensus of $495M as the base business has underperformed our... More
